VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | S1P receptor modulators in the treatment of MS

Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, outlines the different aspects that will be discussed during the symposiumregarding the role of sphingosine-1-phosphate (S1P) receptor modulators and how they fit into the treatment landscape of multiple sclerosis (MS). Presentations during the symposium include an overview of the mechanism of action of S1P receptor modulators, discussions on the patient’s perspective about treatment options, and presentation of new data on the safety of S1P receptor modulation during the COVID-19 pandemic. Dr Tintoré also discusses the development of a consensus on which vaccinations patients with MS should have and when they should have them. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Consulting services and speaking honoraria from: Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Jansen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals.
Receipt grants and research supports from: Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000. Biogen-Idec, Novartis.
Dr Tintoré is co-editor of Multiple Sclerosis Journal-ETC.